• Francesca De Felice, Daniela Musio, Anna Lisa Magnante, Nadia Bulzonetti, Ilaria Benevento, Rossella Caiazzo, and Vincenzo Tombolini.
• Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Rome, Italy. Electronic address: fradefelice@hotmail.it.
• Clin Colorectal Cancer. 2016 Jun 1; 15 (2): e17-22.

PurposeTo report the long-term follow-up data and determine the toxicity rate concerning patients with locally advanced rectal cancer (LARC) treated with an intensified neoadjuvant treatment regimen.Patients And MethodsPatients with histologically proven stage II to III adenocarcinoma of the rectum were included and treated with a trimodal approach. Intensified neoadjuvant treatment (chemoradiotherapy [CRT]) consisted of radiotherapy (total dose 50.4/54 Gy) and concomitant oxaliplatin (50 mg/m(2)/week) and 5-fluorouracil (200 mg/m(2)/5 daily continuous infusion). Surgery was planned 7 to 9 weeks after the end of CRT. Adjuvant chemotherapy was recommended in those patients with lymph node metastasis at diagnosis.ResultsOne hundred patients (median age, 64 years) were eligible. Overall, the 5-year overall survival and disease-free survival (DFS) were 76.4% and 74.5%, respectively. CRT was well tolerated, with only 17% grade 3/4 acute toxicity. Twenty-four patients (24%) had a pathologic complete response (pCR), and only 1 patient had perioperative metastasis. The 5-year DFS were 95.7% and 66.7% for pCR and no-pCR tumor histology, respectively (P = .0275).ConclusionAlthough oxaliplatin is not considered to be a standard treatment, the high 5-year rate of overall survival and DFS, the low severe toxicity rates, and the effective benefit on pCR and perioperative metastasis support an intensified treatment regimen for LARC.Copyright © 2016 Elsevier Inc. All rights reserved.

35 keywords...

hide…